Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P; COMET Investigators. Olsson LG, et al. Eur J Heart Fail. 2007 Aug;9(8):795-801. doi: 10.1016/j.ejheart.2007.07.010. Eur J Heart Fail. 2007. PMID: 17693380 Free article. Clinical Trial.
Six minute walk test.
Olsson L, Swedberg K. Olsson L, et al. Eur Heart J. 2005 Oct;26(20):2209; author reply 2209-10. doi: 10.1093/eurheartj/ehi452. Epub 2005 Aug 16. Eur Heart J. 2005. PMID: 16105847 No abstract available.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S. Ducharme A, et al. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2005.06.036. Am Heart J. 2006. PMID: 16644318
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA; CHARM Investigators. Olsson LG, et al. J Am Coll Cardiol. 2006 May 16;47(10):1997-2004. doi: 10.1016/j.jacc.2006.01.060. Epub 2006 Apr 27. J Am Coll Cardiol. 2006. PMID: 16697316 Free article. Clinical Trial.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Ducharme A, et al. Am Heart J. 2006 Jul;152(1):86-92. Am Heart J. 2006. PMID: 16838426
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators. Kapelios CJ, et al. Eur J Heart Fail. 2019 Nov;21(11):1383-1397. doi: 10.1002/ejhf.1532. Epub 2019 Jun 18. Eur J Heart Fail. 2019. PMID: 31132222 Free article.
26 results